METASTATIC CELLS DETECTION IN LUNGS USING HP HE AND TARGETED CONTRAST AGENT

使用 HP HE 和靶向造影剂检测肺部转移细胞

基本信息

批准号：
8363170
负责人：
Rosa Tamara Branca
金额：
$ 1.23万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-07-01 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8363170
关键词：
Achievement American Cancer Society Breast Bronchoscopy Cancer Detection Cells Choriocarcinoma Clinical Colorectal Common Neoplasm Contrast Media Data Detection Development Diagnosis Disease Disseminated Malignant Neoplasm Drainage procedure Fine needle aspiration biopsy Funding Grant Head and neck structure Helium Image Injection of therapeutic agent Investigation Kidney Lung Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of lung Mammary Neoplasms Metastatic Neoplasm to the Lung Methods Micrometastasis Microscopy Modality Monitor Mus National Center for Research Resources PET/CT scan Patients Pilot Projects Positron-Emission Tomography Primary Neoplasm Principal Investigator Prostate Publications Renal carcinoma Research Research Infrastructure Resources Scanning Screening procedure Sensitivity and Specificity Source Sputum Cytology Screening Techniques Testicular Teratoma Thyroid carcinoma Time United States National Institutes of Health Venous cancer cell cost interest melanoma mortality neoplastic cell osteosarcoma tumor

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. We developed a new method that uses Hyperpolarized Helium MRI and targeted contrast agent to detect metastatic cancer cells in lungs. We aim to establish the sensitivity and specificity of our method with respect to other clinically available techniques, such as PET and CT scan. We plan on scanning breast tumor bearing mice after they received an injection of our contrast agent LHRH-SPION. We will utilize 10 breast tumor mice that have already been imaged with other modalities (CT and PET) and have shown sign of metastatic cancer cells in lungs. We are requesting 5 days of additional MRI time to complete our pilot project of the title above. With this time we expect to generate the necessary data for a high-profile publication, as well as preliminary data for an R01 application. Below are additional details about the project achievements thus far. According to the American Cancer Society, more than 1.44 million people will be diagnosed with cancer, and more than 560 thousand will die of it this year in the US. The high mortality rate in these patients has been attributed to the development of subclinical occult micrometastasis simultaneously with the more easily diagnosed primary tumor. Thus, the search for these micrometastatic cells is an issue of significant clinical interest. Sensitive non-invasive methods are needed both for early metastatic disease detection and to monitor subsequent treatments. We are focusing our investigation on the MRI detection of specifically targeted pulmonary metastases. Pulmonary metastases are common and most frequently occur with tumors that have rich systemic venous drainage, like renal cancers, bone sarcomas, choriocarcinomas, melanomas, testicular teratomas, and thyroid carcinomas. However most pulmonary metastases arise from common tumors, such as breast, colorectal, prostate, bronchial, head-and-neck, and renal and, of course, lung cancers. Pulmonary metastases are present in 20-54% of all patients who die of cancer, and detection of pulmonary metastases is crucial in the treatment of patients with cancer. Current screening techniques in lungs (fine-needle aspiration (FNA), bronchoscopy, sputum cytology, PET, and CT are invasive and/or lack the sensitivity necessary to detect micrometastases, single disseminated cells, or small tumor cell clusters in lungs.

该子项目是利用资源的众多研究子项目之一由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持并且子项目的首席研究员可能是由其他来源提供的，包括其他 NIH 来源。子项目可能列出的总成本代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。我们开发了一种新方法，使用超极化氦 MRI 和靶向造影剂来检测肺部转移癌细胞。我们的目标是确定我们的方法相对于其他临床可用技术（例如 PET 和 CT 扫描）的敏感性和特异性。我们计划在注射我们的造影剂 LHRH-SPION 后对携带乳腺肿瘤的小鼠进行扫描。我们将利用 10 只乳腺肿瘤小鼠，这些小鼠已经通过其他方式（CT 和 PET）进行成像，并显示出肺部转移性癌细胞的迹象。我们请求 5 天的额外 MRI 时间来完成上述标题的试点项目。我们希望利用这段时间为备受瞩目的出版物生成必要的数据，以及 R01 应用程序的初步数据。以下是有关迄今为止项目成就的更多详细信息。据美国癌症协会称，今年美国将有超过144万人被诊断患有癌症，超过56万人将死于癌症。这些患者的高死亡率归因于亚临床隐匿性微转移与更容易诊断的原发肿瘤同时发生。因此，寻找这些微转移细胞是具有重大临床意义的问题。早期转移性疾病检测和监测后续治疗都需要敏感的非侵入性方法。我们的研究重点是 MRI 检测特异性靶向肺转移瘤。肺转移很常见，最常见于具有丰富的全身静脉引流的肿瘤，如肾癌、骨肉瘤、绒毛膜癌、黑色素瘤、睾丸畸胎瘤和甲状腺癌。然而，大多数肺转移源自常见肿瘤，如乳腺癌、结直肠癌、前列腺癌、支气管癌、头颈癌、肾癌，当然还有肺癌。所有死于癌症的患者中有 20-54% 存在肺转移，肺转移的检测对于癌症患者的治疗至关重要。目前的肺部筛查技术（细针抽吸 (FNA)、支气管镜检查、痰细胞学、PET 和 CT）是侵入性的和/或缺乏检测肺部微转移、单个播散细胞或小肿瘤细胞簇所需的灵敏度。